The Use of Nasal Phenylephrine in Infants With Bronchiolitis

Drops of either saline or phenylephrine are placed in the nose of infants less than 12 months of age to determine if it helps them to breathe easier.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchiolitis Bronchial Diseases Bronchitis Infections Lung Diseases Lung Diseases, Obstructive Respiratory Tract Diseases Respiratory Tract Infections

Age range

4 week–12 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 4 weeks to 12 months; admitting diagnosis of bronchiolitis; admitted to hospital's bronchiolitis pathway, admitted during weekdays, need for nasal suctioning.

Exclusion criteria

Congenital heart disease, history of hypertension, previous wheezing, prior use of inhaled corticosteroids, gestational age at birth of <34 weeks.

Treatment and study plan

Phenylephrine

Drug

Primary outcomes

Respiratory Distress Assessment Index at 5 minutes, 60 minutes, and 180 minutes.

Secondary outcomes

Respiratory rate, oxygen saturation and use of supplemental oxygen at 5, 60, and 180 minutes.

Sponsors and collaborators

Lead sponsor

Akron Children's Hospital

Other

Registry information

Official study title

A Randomized, Double-Blinded Placebo Control Trial of Nasal Phenylephrine in Infants With Bronchiolitis

Important dates

Study start: 2005
Primary completion: 2005
Study completion: 2005
First posted: Sep 8, 2006
Registry last updated: Jan 12, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed